Core Insights - Illumina reported Q3 2025 financial results that exceeded guidance for revenue and earnings, driven by growth in the clinical segment, marking a return to growth outside of China [2][9]. Financial Performance - Revenue for Q3 2025 was $1,084 million, flat compared to Q3 2024 [9]. - GAAP operating margin was 21.0%, while non-GAAP operating margin was 24.5% for Q3 2025 [9][22]. - GAAP diluted EPS was $0.98, and non-GAAP diluted EPS was $1.34 for Q3 2025 [9][22]. - Net income for Q3 2025 was $150 million, down from $642 million in Q3 2024 [9][24]. Cash Flow and Expenditures - Cash flow from operations was $284 million, compared to $316 million in the prior year [3][20]. - Free cash flow for Q3 2025 was $253 million, down from $284 million in the prior year [3][20]. - Capital expenditures for the quarter were $31 million [3]. Guidance and Outlook - The company expects a total revenue decline in the range of (1.5%) to (0.5%) for fiscal year 2025, an improvement from the previous range of (2.5%) to (1.5%) [9]. - Revenue growth outside of China is projected to be between 0.5% and 1.5% on a constant currency basis [9]. - Non-GAAP operating margin guidance has been raised to a range of 22.75% to 23% [9]. Recent Developments - Illumina launched several new products and initiatives, including a 5-base solution for genomic insights and BioInsight for technology-driven discovery [10]. - The company expanded its personalized cancer care efforts through new pharmaceutical partnerships [10].